Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00971308 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00971308 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 37 participants.
The verdict
NCT00971308, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.
Interventions
- DRUG BMS-824393
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00971308
The ClinicalTrials.gov registry entry for NCT00971308 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-824393 is the first listed.
NCT00971308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00971308 about?
NCT00971308 is a clinical study titled "Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus". The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.
What is the current status of trial NCT00971308?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2009-10. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00971308?
The interventions under investigation include: BMS-824393 (DRUG).
Who is sponsoring clinical trial NCT00971308?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.